Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
32.58
+0.29 (0.90%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.05 - 32.87
52 week 27.51 - 39.94
Open 32.30
Vol / Avg. 142,812.00/428,010.00
Mkt cap 1.35B
P/E 72.06
Div/yield     -
EPS 0.45
Shares 41.74M
Beta 1.33
Inst. own 106%
Oct 29, 2014
Q3 2014 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 9, 2014
Acorda Therapeutics Inc at Morgan Stanley Healthcare Conference - 2:05PM EDT - Add to calendar
Sep 4, 2014
Acorda Therapeutics Inc at Robert W. Baird & Co. Inc Health Care Conference - 10:50AM EDT - Add to calendar
Sep 3, 2014
Acorda Therapeutics Inc at Citi Biotech Conference Add to calendar
Sep 3, 2014
Acorda Therapeutics Inc at FBR & Co Inaugural Healthcare Conference Add to calendar
Jul 31, 2014
Q2 2014 Acorda Therapeutics, Inc. Earnings Release
Jul 31, 2014
Q2 2014 Acorda Therapeutics Inc Earnings Call
Jun 5, 2014
Acorda Therapeutics, Inc. Annual Shareholder Meeting
Jun 2, 2014
Acorda Therapeutics, Inc. at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 4.82% 4.89%
Operating margin 11.30% 9.03%
EBITD margin - 11.11%
Return on average assets 2.42% 2.80%
Return on average equity 3.95% 3.98%
Employees 421 -
CDP Score - -

Address

420 Saw Mill River Road
ARDSLEY, NY 10502
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Lauren M. Sabella Executive Vice President - Commercial Development
Age: 53
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Andrew Asa Hindman Chief Business Development Officer
Bio & Compensation  - Reuters
David W. Lawrence Chief - Business Operations
Age: 56
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 50
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters